
Frédéric Calon
Chercheur universitaire
Axe Neurosciences
Publications
View all-
article Vandal M, Institoris A, Reveret L, Korin B, Gunn C, Hirai S, Jiang Y, Lee S, Lee J, Bourassa P, Mishra RC, Peringod G, Arellano F, Belzil C, Tremblay C, Hashem M, Gorzo K, Elias E, Yao J, Meilandt B, Foreman O, Roose-Girma M, Shin S, Muruve D, Nicola W, Körbelin J, Dunn JF, Chen W, Park SK, Braun AP, Bennett DA, Gordon GRJ, Calon F, Shaw AS, Nguyen MD
Loss of endothelial CD2AP causes sex-dependent cerebrovascular dysfunction
Neuron 113 (6), 2025.
-
article Rhea EM, Leclerc M, Yassine HN, Capuano AW, Tong H, Petyuk VA, Macauley SL, Fioramonti X, Carmichael O, Calon F, Arvanitakis Z
State of the Science on Brain Insulin Resistance and Cognitive Decline Due to Alzheimer’s Disease
Aging Dis 15 (4), 2024.
-
article Leclerc M, Tremblay C, Bourassa P, Schneider JA, Bennett DA, Calon F
Lower GLUT1 and unchanged MCT1 in Alzheimer’s disease cerebrovasculature
J Cereb Blood Flow Metab 44 (8), 2024.
Projects
- Laboratoire international associé (LIA) OptiNutriBrain, from 2015-03-01 to 2026-03-01
- Nutrition and brain health, from predictive biology to disease prevention and treatment - Food4BrainHealth, from 2019-03-18 to 2026-03-17
- Team 7.1.1: Investigation of cerebrovascular pathology using cerebral microvessel extracts and in animal models, from 2019-04-01 to 2026-03-31
- FGF-21 in Alzheimer's disease, from 2022-10-01 to 2027-09-30
- Health Research Training to Address Vascular Contributions to Cognitive Decline: the Vascular Training (VAST) Platform, from 2022-01-01 to 2027-12-31
- Rôle du facteur de croissance placentaire (PIGF) comme potentiel biomarqueur de la contribution vasculaire aux troubles cognitifs associés à la maladie d’Alzheimer., from 2023-10-24 to 2025-11-01
- Institut sur la nutrition et les aliments fonctionnels (INAF), from 2024-04-01 to 2030-03-31
- Consortium pour l’identification précoce de la maladie d’Alzheimer (CIMA-Q) : renforcer l’intersectorialité, le rayonnement et le potentiel de découverte., from 2024-04-01 to 2028-03-31
- Bioactivité des acides animés de type mycosporine dans les algues rouges du Fleuve Saint-Laurent (NeuronAlg 2.0), from 2024-11-01 to 2027-10-31
- Étude de la sélénonéine en tant que nouveau biomarqueur nutritionnel et agent thérapeutique dans les maladies neurodégénératives, from 2024-12-18 to 2026-03-31
- Institut sur la nutrition et les aliments fonctionnels (INAF), from 2017-04-01 to 2024-03-31
- Multi-pathway cholesterol depletion on top of FOLFIRINOX in newly diagnosed metastatic pancreatic adenocarcinoma: a feasibility and proof-of-concept study, from 2019-10-01 to 2025-03-31
- Phase Two of the Canadian Consortium on Neurodegeneration in Aging, from 2019-04-01 to 2024-03-31
- How does insulin interact with the blood-brain barrier? Therapeutic implications for diabetes and Alzheimer’s disease, from 2020-04-01 to 2025-03-31
- Mechanisms of endocytosis and transcytosis into endothelial cells of the blood-brain barrier, from 2020-04-01 to 2025-03-31
- Plateforme Biomarqueurs et cibles thérapeutiques – Cohorte clinique CIMA-Q, from 2019-04-01 to 2025-03-31
- Elimination of senescent endothelial cells to prevent vascular dementia in aging atheroscierotic mice, from 2019-10-01 to 2024-09-30
- Fatty acid metabolism in carriers of apolipoprotein E. epsilon 4 allele: determining the blood-to-brain link, from 2020-04-01 to 2025-03-31
- Risk factors and markers for early detection of Alzheimer's Disease: focus on early-life stress, inflammation and lipid mediators, from 2021-12-01 to 2024-11-30
- Évaluation des conditions de culture optimales chez la macroalgue Palmaria palmata pour la production d’acides aminés analogues à la mycosporine et étude de leur biodisponibilité systémique et cérébrale chez la souris, from 2022-11-09 to 2023-11-08
- Blueberry polyphenol metabolites: biodistribution and mechanisms of protection at the blood-brain barrier, from 2023-08-25 to 2025-03-31
- Bourse de voyage de Caroline Dallaire Théroux, from 2024-04-01 to 2025-03-31